Clinical trial
A Phase II, Open-Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
NCT00920556 is registered in ClinicalTrials.gov with Sirtris, a GSK Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open-Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
- Lead sponsor
- Sirtris, a GSK Company
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- March 30, 2009
- Completion date
- November 4, 2010
- Enrollment
- 24 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.